Hong Kong Stock Market Update: Hengrui Pharma Surges Nearly 4% in Late Trading Following Dual Clinical Trial Approvals

China's Jiangsu Hengrui Climbs on Clinical Trial Approval for Stroke Drug

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Recaticimab Injection

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.17% on Sept 10 from 6.56% - HKEX

Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials

Big Pharma is Pouring Billions into China's Biotechs

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets

Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets

Jiangsu Hengrui Pharmaceuticals Says Unit's Ribupatide Injection Marketing Application Accepted by China's Drug Regulator

Hengrui Pharma Wins China Clinical Trial Nod For Two Weight Management Products

Hengrui Pharmaceuticals Gets China Nod to Trial Two Tumor Drugs

Jiangsu Hengrui Medicine Announces First Extraordinary Shareholders Meeting

HENGRUI PHARMA Advances Pipeline with SHR-1179 Injection Clinical Trial Approval

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.21% on SEP 2 from 5.92% - HKEX

Hengrui Pharma Subsidiary Gains Clinical Trial Approval for Weight Management Drug Candidate

August Buyback Report: 277 A-Share Firms Spend Over 13 Billion Yuan, More Than Half Beat the Shanghai Composite, Gaozheng Explosive Surges 68% in a Month

Evaluating the Potential Value of Hengrui's HRS-9531 in an Intensifying GIP Competitive Landscape

Hengrui Pharma's HRS-7535 Tablet Marketing Authorization Application Accepted by China's NMPA

Hengrui Pharma Has Not Yet Initiated Its A-Share Buyback Program as of End-August